Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Cincor Pharma, Inc. (CINC)  
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 43,764,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $0 - $0
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   CinCor Pharma is a biopharmaceutical company focused on developing its primary clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. CIN-107 is an oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland. CIN-107 inhibits aldosterone synthase activity, providing a differentiated mechanism for lowering aldosterone activity via a reduction of aldosterone synthesis, with the goal of providing an improved treatment for patients suffering from hypertension, or high blood pressure. Co. is developing CIN-107 for the indication of chronic kidney disease and primary aldosteronism.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 1,905,333
Total Buy Value $0 $0 $0 $57,159,990
Total People Bought 0 0 0 6
Total Buy Transactions 0 0 0 6
Total Shares Sold 0 0 0 6,006
Total Sell Value $0 $0 $0 $86,011
Total People Sold 0 0 0 2
Total Sell Transactions 0 0 0 2
End Date 2024-02-08 2023-11-07 2023-05-09 2022-05-09

   
Records found: 49
  Page 1 of 2  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   5am Opportunities I (gp), Llc 10% Owner   –       –       •   2023-02-24 4 D $0.00 $0 I/I (4,937,646) 0     -
   Freeman Mason Chief Medical Officer   •       –      –    2023-02-24 4 D $0.00 $0 I/I (100) 0     -
   Freeman Mason Chief Medical Officer   •       –      –    2023-02-24 4 D $0.00 $0 D/D (40,000) 0     -
   Freeman Mason Chief Medical Officer   •       –      –    2023-02-24 4 D $0.00 $0 D/D (2,494) 40,000     -
   Sofinnova Venture Partners X, L.p. 10% Owner   –       –       •   2023-02-24 4 D $0.00 $0 I/I (6,073,949) 0     -
   Sofinnova Venture Partners X, L.p. 10% Owner   –       –       •   2023-02-24 4 D $0.00 $0 D/D (19,608) 0     -
   Sofinnova Venture Partners X, L.p. 10% Owner   –       –       •   2023-02-24 4 D $0.00 $0 D/D (9,803) 19,608     -
   Pearce Catherine Chief Operating Officer   •       –      –    2023-02-24 4 D $0.00 $0 I/I (1,500) 0     -
   Pearce Catherine Chief Operating Officer   •       –      –    2023-02-24 4 D $0.00 $0 D/D (15,000) 0     -
   Pearce Catherine Chief Operating Officer   •       –      –    2023-02-24 4 D $0.00 $0 D/D (140,149) 15,000     -
   Kalb Michael Wayne EVP & Chief Financial Officer   •       –      –    2023-02-24 4 D $0.00 $0 D/D (202,437) 0     -
   De Garidel Marc Chief Executive Officer   •       •      –    2023-02-24 4 D $0.00 $0 D/D (200,000) 0     -
   De Garidel Marc Chief Executive Officer   •       •      –    2023-02-24 4 D $0.00 $0 D/D (12,500) 200,000     -
   Pearce Catherine Chief Operating Officer   •       –      –    2023-01-26 4 A $0.00 $0 D/D 15,000 155,149     -
   Kalb Michael Wayne EVP & Chief Financial Officer   •       –      –    2023-01-26 4 A $0.00 $0 D/D 177,000 202,437     -
   Freeman Mason Chief Medical Officer   •       –      –    2023-01-26 4 A $0.00 $0 D/D 40,000 42,500     -
   De Garidel Marc Chief Executive Officer   •       •      –    2023-01-26 4 A $0.00 $0 D/D 200,000 212,500     -
   Pearce Catherine Chief Operating Officer   •       –      –    2023-01-11 4 D $28.75 $114,914 D/D (3,997) 140,149     -
   Pearce Catherine Chief Operating Officer   •       –      –    2023-01-11 4 OE $0.00 $0 D/D 13,235 144,146     -
   Sofinnova Venture Partners X, L.p. 10% Owner   –       –       •   2022-11-28 4 S $14.32 $85,920 I/I (6,000) 0     -
   Kalb Michael Wayne EVP & Chief Financial Officer   •       –      –    2022-11-04 4 A $0.00 $0 D/D 25,437 25,437     -
   Sofinnova Capital Ix 10% Owner   –       –       •   2022-08-15 4 B $30.00 $3,999,990 I/I 133,333 4,220,979 1.5     -
   5am Opportunities Ii, L.p. 10% Owner   –       –       •   2022-08-15 4 B $30.00 $18,000,000 I/I 600,000 487,333 1.5     -
   Healy James Director   –       •       •   2022-08-11 4 B $30.00 $15,180,000 I/I 506,000 6,000 2.25     -
   General Atlantic (spv) Gp, Llc 10% Owner   –       –       •   2022-08-11 4 B $30.00 $2,490,000 I/I 83,000 4,209,470 1.5     -
  49 Records found
  1  2   
  Page 1 of 2
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us